Advanced Prenatal Therapeutics, Inc. ("APT") is pleased to have
received the California Investment Forum (CIF) 2024 Innovation
Award for Breakthrough Medical Technology in Diagnosis and
Treatment in recognition of APT's breakthrough technology, the
Targeted Apheresis Column for Preeclampsia (TAC-PE). APT's
technology holds promise to minimize the clinical symptoms
associated with preeclampsia and enable the pregnancy to be
prolonged by days or weeks, potentially leading to full term
pregnancies, better outcomes for mothers and babies, and lower
healthcare costs.
LAGUNA
HILLS, Calif., May 20, 2024
/PRNewswire-PRWeb/ -- Advanced Prenatal Therapeutics, Inc.
(APT) is pleased to have received the California Investment Forum
(CIF) 2024 Innovation Award for Breakthrough Medical Technology in
Diagnosis and Treatment in recognition of APT's breakthrough
technology, the Targeted Apheresis Column for Preeclampsia
(TAC-PE). APT's technology holds promise to minimize the clinical
symptoms associated with preeclampsia, a leading cause of premature
birth.
The TAC-PE may prolong pregnancy by days or
weeks, potentially to full term, leading to better outcomes for
both mothers and babies.
The Award was given at the California Investment Forum 2024, an
event taking place on May 8-11 at the
Anaheim Majestic Garden Hotel in Anaheim,
California. The forum featured groundbreaking companies from
over 15 countries and across multiple sectors such as
biotechnology, AI, and renewable energy. James Smith, Ph.D., President and CEO of APT,
presented the Company's breakthrough technology on the second day
of the conference. The presentation was well-received by the
Forum's attendants, a group of influential leaders and experts
committed to catalyzing global economic growth through innovation.
APT's VP of Business Development, Daniel
Thiel, accepted the award on behalf of APT on May 10th from California State Controller
Malia Cohen along with recognition
from Treasurer Fiona Ma.
The TAC-PE is a novel medical device in development that filters
off elevated pathogenic factors (including sFlt-1 receptor)
associated with causing preeclampsia from the pregnant mothers'
blood in a safe process similar to dialysis. The technology may
enable pregnancy to be prolonged by days or weeks, potentially
leading to full term pregnancies, better outcomes for mothers and
babies, and lower healthcare costs. The TAC-PE has already received
Breakthrough Device Designation by the US FDA.
Media Contact
Dan Thiel, Investor Relations,
Advanced Prenatal Therapeutics, Inc., 1 3109513282,
dthiel@advancedprenatal.com, www.advancedprenatal.com
View original
content:https://www.prweb.com/releases/advanced-prenatal-therapeutics-receives-breakthrough-innovation-award-at-the-california-investment-forum-2024-302149740.html
SOURCE Advanced Prenatal Therapeutics, Inc.